Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer
Open Access
- 13 September 2021
- journal article
- research article
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2021, 1-8
Abstract
Objective. Prostate cancer (PCa) is considered the most serious cancer in the world. Nevertheless, the accuracy of current biomarkers, such as pathological staging, Gleasons score, and serum prostate-specific antigen (PSA) levels, is limited. FOXO1 is a key downstream effector of PTEN and a tumor suppressor in PCA, which has been reported extensively. However, the clinical relevance of FOXO1 in PCa remains unclear. Methods. In this study, we first detected its expression in four public databases to explore the clinical role of FOXO1. Verification of the knockdown effect of FOXO1 siRNA was performed by real-time PCR analysis. Changes in cell viability were assessed using cell counting kit-8 (CCK-8) assays. In addition, we verified the effect of FOXO1 on the PCa cell cycle using a cell cycle assay. Results. Herein, we found that FOXO1 was significantly downregulated in PCa tissues and was significantly associated with Gleasons score, age, biochemical recurrence (BCR), and lymph node (LN) status, while FOXO1 expression was independent of pathological staging and preoperative PSA levels. The Kaplan-Meier survival analysis showed that PCA patients with high FOXO1 expression were less likely to develop BCR compared with patients with low FOXO1 expression. In terms of function, FOXO1 inhibition significantly promoted the proliferation and cell cycle progression of PCa cells. Conclusions. In summary, our study suggests that FOXO1 may be one of the prognostic factors that describe the risk of PCa for BCR. These results suggest that FOXO1 may be a therapeutic target for PCa.Keywords
Funding Information
- Natural Science Foundation of Minhang District Science and Technology Commission (2020MHZ070, 2019MW09)
This publication has 20 references indexed in Scilit:
- miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cellsMedical Oncology, 2014
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2014
- Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal TherapiesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Biochemical Recurrence After Radical Prostatectomy: Multiplicative Interaction Between Surgical Margin Status and Pathological StageJournal of Urology, 2010
- Changes in Gleason Score Grading and Their Effect in Predicting Outcome After Radical ProstatectomyUrology, 2009
- Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate CancerClinical Cancer Research, 2009
- Dynamic FoxO transcription factorsJournal of Cell Science, 2007
- Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cellsOncogene, 2007
- Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of MalignancyJournal of Clinical Oncology, 2004
- Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cellsOncogene, 2000